Axsome doses first patient in PARADIGM Phase 3 trial of solriamfetol for MDD

Axsome Therapeutics, Inc.

First patient dosed in Phase 3 PARADIGM trial of solriamfetol for major depressive disorder.
Randomized, double-blind, placebo-controlled trial with ~300 patients (1:1 ratio, 300 mg or placebo for 6 weeks).
Primary endpoint is change in Montgomery-Åsberg Depression Rating Scale (MADRS).
Solriamfetol is an investigational treatment; Axsome specializes in CNS disorders.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.